The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recogni | In ...

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder in a ...

It’s been a whirlwind year for Joerg Moeller, M.D. After being appointed CEO of BenevolentAI in January, Moeller is now out ...

Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Tarver took the position in late July after the announcement that CDRH’s director of the past 15 years, Jeff Shuren, M.D., ...

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...

Just as Smita Gopinath, Ph.D., was setting up her microbiology and immunology lab at Harvard T.H. Chan School of Public ...

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small ...

Noema included other assessments of Tourette symptoms as secondary endpoints. Across the 14 people in the primary analysis, ...